Exemestane , a steroidal aromatase inhibitor , reduced invasive breast cancer incidence by @ % among @,@ postmenopausal women randomly assigned to exemestane ( @ mg per day ) compared with placebo in the National Cancer Institute of Canada ( NCIC ) Clinical Trials Group MAP @ ( Mammary Prevention @ ) trial , but effects on quality of life ( QOL ) were not fully described .